MSI-H/dMMR + TMB-H + PD-L1 negative
|
Uterine Cancer
|
MSI-H/dMMR + TMB-H + PD-L1 negative
|
Uterine Cancer
|
pembrolizumab Sensitive: C4 – Case Studies
|
pembrolizumab Sensitive: C4 – Case Studies
|
MSI-H/dMMR + TMB-H + PD-L1 negative
|
Pancreatic Cancer
|
MSI-H/dMMR + TMB-H + PD-L1 negative
|
Pancreatic Cancer
|
paclitaxel + gemcitabine Sensitive: C4 – Case Studies
|
paclitaxel + gemcitabine Sensitive: C4 – Case Studies
|
MSI-H/dMMR + TMB-H + PD-L1 negative
|
Pancreatic Cancer
|
MSI-H/dMMR + TMB-H + PD-L1 negative
|
Pancreatic Cancer
|
pembrolizumab Sensitive: D – Preclinical
|
pembrolizumab Sensitive: D – Preclinical
|